NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme
Stevenage, UK, 22 February 2023 - NRG Therapeutics, Ltd., an…
22 February 2023/by WebadmNRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
Gilles Ouvry Ph.D, appointed to newly created position of…
9 February 2023/by WebadmNRG Therapeutics Announces £16 million Series A to Advance Mitochondrial Therapeutics for Parkinson’s and ALS
£16 million Series A led by Omega Funds, to advance disease-modifying…
9 November 2022/by WebadmNRG Therapeutics Selects Domainex to be its Integrated Drug Discovery Partner for its Biomedical Catalyst Funded Parkinson’s Disease Project
NRG Therapeutics Ltd., an innovative neuroscience company targeting…
30 June 2022/by WebadmNRG Therapeutics Announces £2.68M Innovate UK Award to Develop New Medicines to Treat Parkinson’s and Motor Neurone Disease
£2.68 million Biomedical Catalyst (BMC) early-stage award…
30 May 2022/by WebadmNRG Therapeutics Completes MND Therapeutic Analysis Project with Medicines Discovery Catapult Supported by an Innovate UK EDGE Grant
NRG’s second therapeutic programme to explore brain penetrant…
1 March 2022/by WebadmNRG Therapeutics Launches MND Drug Discovery Programme and Announces new Collaboration in Australia
NRG’s second therapeutic programme to explore brain penetrant…
16 December 2021/by WebadmParkinson’s UK invests a further £490k in NRG Therapeutics to Progress Parkinson’s Drug Discovery Programme
NRG Therapeutics Ltd (“NRG” or “company”), an innovative…
23 August 2021/by WebadmNRG Therapeutics Awarded $500K Grant from The Michael J. Fox Foundation to Progress Parkinson’s Programme
NRG Therapeutics Ltd (“NRG” or “company”), an innovative…
29 July 2021/by Webadm
